Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Denali Therapeutics Inc (DNLI)

263 + Investors. Track Smart Money conviction in DNLI. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +21
Streak
4Q ▲
Buyers last Q
63%

Smart Money Signals — DNLI

Based on 268 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added DNLI than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
268 hedge funds hold DNLI right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +23% more funds vs a year ago

fund count last 6Q
+50 new funds entered over the past year (+23% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 63% buying

161 buying96 selling
Last quarter: 161 funds were net buyers (56 opened a brand new position + 105 added to an existing one). Only 96 were sellers (61 trimmed + 35 sold completely). A clear majority buying is a strong confirmation signal.
➡️

Steady new buyers — ~56 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 48 → 33 → 52 → 56. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

50% of holders stayed for 2+ years

■ 50% conviction (2yr+) ■ 23% medium ■ 27% new
134 out of 268 hedge funds have held DNLI for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

37 → 48 → 33 → 52 → 56 new funds/Q
New funds entering each quarter: 48 → 33 → 52 → 56. A growing number of institutions are discovering DNLI each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 59% veterans vs 30% newcomers

■ 59% veterans ■ 11% 1-2yr ■ 30% new
Entry-cohort mix of 279 holders: 164 (59%) are 2+ year veterans, 31 entered 1–2 years ago, and 84 (30%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 46% AUM from top-100 funds

46% from top-100 AUM funds
52 of 264 holders are among the 100 largest funds by AUM, controlling 46% of total institutional value in DNLI. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.9
out of 10
Low Exit Risk
Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — DNLI

In 2026 Q1, 161 hedge funds were net buyers of DNLI (56 opened a new position, 105 added to an existing one), while 96 reduced or exited (61 trimmed, 35 sold completely) — a 63% buyer ratio, indicating clear institutional accumulation. This marks 4 consecutive quarters of net institutional buying — a persistent conviction signal. 46% of total institutional value in DNLI is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +21 funds (more new holders than closures). Total institutional holders: 268.

Hedge Fund Ownership: DNLI

How many hedge funds hold DNLI — quarterly history vs. share price
Quarterly hedge fund ownership of DNLI vs. share price

Market Analysis: DNLI

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: DNLI

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Denali Therapeutics Inc (DNLI) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much DNLI has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 45d ago
DNLI
-1.9%
XLV
+6.1%

DNLI outperformed XLV by -8.0% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 0d ago
DNLI
+0.0%
XLV
+0.0%

Since the filing became public, DNLI outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

18 top-rated funds 3 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
2.9
/ 10
conviction
Hedge Fund Positioning: DNLI
2026 Q2 Stats Unlock in 5 days 263 + Investors

Track Smart Money conviction in DNLI. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 263 247 6.48%
13F Shares 148M 145M 1.75%
Total Value $2.61B $2.33B 12.07%
New Positions 56 52 +4
Increased Positions 104 85 +19
Closed Positions 36 38 -2
Reduced Positions 56 71 -15
Total Calls 9 4 125.0%
Total Puts 6 1 500.0%
PUT/CALL Ratio 0.67 0.25 Bullish

Statistics: DNLI

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

263 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in DNLI. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 DNLI holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Cercano Management LLC 1.55% 625,000 $16.1M
2 Privium Fund Management B.V. 1.09% 229,857 $5.9M
3 Lumbard & Kellner, LLC 0.77% 98,282 $2.5M
4 Siren, L.L.C. 0.73% 1,396,513 $35.9M
5 Yorktown Management & Research Co Inc 0.51% 32,100 $826K
6 1492 Capital Management LLC 0.50% 66,368 $1.7M
7 Temasek Holdings (Private) Ltd 0.48% 7,012,974 $180.4M
8 Rhenman & Partners Asset Management AB 0.43% 179,000 $4.6M
9 Virtus Investment Advisers, LLC 0.32% 53,688 $1.4M
10 Baillie Gifford & Co 0.28% 11,960,230 $307.6M
11 Bayforest Capital Ltd 0.27% 11,437 $294K
12 Phocas Financial Corp. 0.25% 71,197 $1.8M
13 Segall Bryant & Hamill, LLC 0.16% 519,483 $13.4M
14 Candriam S.C.A. 0.14% 1,189,886 $30.6M
15 PSP Research LLC 0.12% 8,463 $218K
16 Integral Health Asset Management, LLC 0.10% 100,000 $2.6M
17 E. Ohman J:or Asset Management AB 0.10% 160,000 $4.1M
18 Knights of Columbus Asset Advisors LLC 0.09% 67,591 $1.7M
19 Inceptionr LLC 0.09% 13,632 $351K
20 Pier 88 Investment Partners LLC 0.08% 12,700 $327K
21 Pictet Asset Management Holding SA 0.07% 2,791,206 $71.9M
22 Contravisory Investment Management, INC. 0.07% 14,674 $377K
23 Banque Cantonale Vaudoise 0.06% 17,926 $461K
24 Lynx1 Capital Management LP 0.06% 11,658 $300K
25 Edmond de Rothschild Holding S.A. 0.06% 165,080 $4.2M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Denali Therapeutics Inc (DNLI)

What does the Smart Money Trend signal show for DNLI?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added DNLI than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for DNLI?

More buyers than sellers — 63% buying: Last quarter: 161 funds were net buyers (56 opened a brand new position + 105 added to an existing one). Only 96 were sellers (61 trimmed + 35 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for DNLI holders?

Elite ownership — 46% AUM from top-100 funds: 52 of 264 holders are among the 100 largest funds by AUM, controlling 46% of total institutional value in DNLI. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held DNLI?

50% of holders stayed for 2+ years: 134 out of 268 hedge funds have held DNLI for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Denali Therapeutics Inc (DNLI) following the 2026 Q2 hedge fund 13F filings?

As of today, DNLI has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), DNLI has gained -1.9% vs +6.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →